Summit Therapeutics Inc. (SMMT)
Automate Your Wheel Strategy on SMMT
With Tiblio's Option Bot, you can configure your own wheel strategy including SMMT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SMMT
- Rev/Share 0.0
- Book/Share 0.4665
- PB 37.9938
- Debt/Equity 0.0187
- CurrentRatio 10.6302
- ROIC -0.4826
- MktCap 13075372683.0
- FreeCF/Share -0.2351
- PFCF -75.343
- PE -54.339
- Debt/Assets 0.0168
- DivYield 0
- ROE -0.705
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 2
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | SMMT | Citigroup | Neutral | Buy | $23 | $35 | March 26, 2025 |
| Initiation | SMMT | Cantor Fitzgerald | -- | Overweight | -- | -- | March 21, 2025 |
| Initiation | SMMT | Evercore ISI | -- | Outperform | -- | $30 | March 12, 2025 |
| Initiation | SMMT | Goldman | -- | Buy | -- | $42 | Feb. 28, 2025 |
| Initiation | SMMT | Truist | -- | Buy | -- | $35 | Jan. 8, 2025 |
| Initiation | SMMT | Wells Fargo | -- | Overweight | -- | $30 | Dec. 11, 2024 |
| Initiation | SMMT | Jefferies | -- | Buy | -- | $31 | Dec. 6, 2024 |
| Downgrade | SMMT | Citigroup | Buy | Neutral | $19 | $23 | Sept. 27, 2024 |
News
Down 36.7% in 4 Weeks, Here's Why Summit Therapeutics (SMMT) Looks Ripe for a Turnaround
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Summit Therapeutics (SMMT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Read More
Summit Therapeutics: Market Overreaction Creates Opportunity
Published: June 02, 2025 by: Seeking Alpha
Sentiment: Positive
Summit's ivonescimab showed a 48% reduction in disease progression risk in EGFR-mutant lung cancer — a best-in-class result in a tough-to-treat population. Overall survival data is trending positive but has not yet reached statistical significance; further follow-up may tip the balance. The recent stock sell-off reflects regulatory uncertainty rather than drug failure, creating a potential buying opportunity for long-term investors.
Read More
Summit Therapeutics Stock Nosedives on Mixed NSCLC Study Results
Published: June 02, 2025 by: Zacks Investment Research
Sentiment: Negative
SMMT plunges 31% as its NSCLC drug shows strong PFS but misses statistical significance on survival data.
Read More
Is SMMT Stock A Buy After Its Recent Plunge?
Published: June 02, 2025 by: Forbes
Sentiment: Negative
Summit Therapeutics (NASDAQ: SMMT) experienced a significant 30% decrease in its stock on Friday, May 30th, closing at $18. This sudden decline came even though the stock had doubled within the past year, driven by favorable updates regarding its lung cancer medication, ivonescimab.
Read More
Is Beaten-Down Summit Therapeutics Stock a Bad-News Buy?
Published: June 02, 2025 by: The Motley Fool
Sentiment: Negative
Shares of Summit Therapeutics (SMMT -30.39%) tanked more than 30% on Friday, May 30. Such dramatic price swings aren't unusual in the biotechnology industry; in this case, disappointing data from an important clinical trial drove the stock down.
Read More
Summit Therapeutics: Moving Stock To 'Hold' Rating After Phase 3 HARMONi Data Release
Published: May 30, 2025 by: Seeking Alpha
Sentiment: Negative
PFS in Phase 3 HARMONi study, using ivonescimab + chemotherapy to treat patients with EGFR 2nd-line NSCLC, was met with statistical significance, but OS was not. OS data not being met in a statistically significant manner puts doubt on company's ability to file a BLA of ivonescimab for the treatment of patients with EGFR 2nd-line NSCLC. The global non-small cell lung cancer therapeutics market is expected to reach $37.49 billion by 2035.
Read More
Summit Therapeutics Study Is a Win for China Biopharma Deals. Why the Stock Is Down.
Published: May 30, 2025 by: Barrons
Sentiment: Positive
The trial was meant to answer the biggest question in biotech: What happens when U.S. companies test promising new Chinese cancer immunotherapies in western countries?
Read More
Does Summit Therapeutics (SMMT) Have the Potential to Rally 44.6% as Wall Street Analysts Expect?
Published: May 26, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Summit Therapeutics (SMMT) points to a 44.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Wall Street Analysts Predict a 33.4% Upside in Summit Therapeutics (SMMT): Here's What You Should Know
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 33.4% upside potential for Summit Therapeutics (SMMT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Summit Therapeutics Q1 Loss Narrower Than Expected, Sales Nil
Published: May 02, 2025 by: Zacks Investment Research
Sentiment: Positive
SMMT's first-quarter earnings outpace estimates. The company also provides updates on its pipeline.
Read More
Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China
Published: April 25, 2025 by: Business Wire
Sentiment: Neutral
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today noted that Akeso, Inc. (Akeso, HKEX Code: 9926.HK) announced that ivonescimab was approved by the Chinese Health Authorities, the National Medical Products Administration (NMPA), for a second indication based on the results of the Phase III clinical trial, HARMONi-2 or AK112-303. HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced o.
Read More
Summit Therapeutics: Multibillion Dollar NSCLC Potential Faces Growing Competition
Published: April 14, 2025 by: Seeking Alpha
Sentiment: Neutral
Summit Therapeutics' ivonescimab shows promising results in China, outperforming Keytruda in PD-L1 positive advanced NSCLC, with potential $10 billion peak annual revenue. Fierce competition exists in the PD-1/VEGF bispecific antibody space, with major players like Merck and BioNTech entering the market. Summit's financial health shows a significant cash runway into late 2027, despite high R&D and G&A expenses and no revenue generation.
Read More
3 Growth Stocks That Have Dwarfed Nvidia's Returns Over the Past 12 Months
Published: April 03, 2025 by: The Motley Fool
Sentiment: Positive
Is the excitement surrounding chipmaker Nvidia fading? As of Monday, shares of the tech giant were down 19% since the start of 2025.
Read More
Why Summit Therapeutics Stock Slipped Today
Published: March 26, 2025 by: The Motley Fool
Sentiment: Negative
Summit Therapeutics (SMMT -2.25%) stock did better than a lot of other equities during an otherwise forgettable trading session on Wednesday. In contrast to other titles that fell notably, Summit more or less kept pace with the S&P 500 (^GSPC -1.12%), managing to dip by a relatively modest 2.25% in price.
Read More
Analyst Initiates Coverage On 'Undervalued' Summit Therapeutics
Published: March 24, 2025 by: Benzinga
Sentiment: Positive
On Friday, Cantor Fitzgerald initiated coverage on Summit Therapeutics Inc. SMMT, citing shares as 67% undervalued.
Read More
This Unstoppable Biotech Stock Just Became an Even Better Buy
Published: March 19, 2025 by: The Motley Fool
Sentiment: Positive
Last year, Summit Therapeutics (SMMT -1.24%) was one of the stars of the biotech industry. The company's shares soared following a significant clinical win.
Read More
Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs
Published: February 24, 2025 by: PRNewsWire
Sentiment: Neutral
HONG KONG , Feb. 24, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its partner on ivonescimab, Summit Therapeutics Inc. (NASDAQ: SMMT) has entered into a clinical trial collaboration with Pfizer Inc. (NYSE: PFE) to evaluate ivonescimab, a novel, investigational PD-1 / VEGF bispecific antibody, in combination with several of Pfizer's antibody drug conjugates (ADCs) across multiple solid tumor settings. "Rapidly developing novel mechanisms that go beyond what is currently available to patients and physicians is what we believe will make the most significant impact for those facing the greatest challenges from cancer today," noted …
Read More
Summit Therapeutics: Mid-2025 NSCLC Data Could Further Entrench Ivonescimab Program
Published: February 24, 2025 by: Seeking Alpha
Sentiment: Neutral
Summit Therapeutics: Mid-2025 NSCLC Data Could Further Entrench Ivonescimab Program
Read More
Pfizer: What The Summit Therapeutics Deal Brings
Published: February 24, 2025 by: Seeking Alpha
Sentiment: Neutral
Pfizer: What The Summit Therapeutics Deal Brings
Read More
3 Stocks That Could Trounce the Market in 2025
Published: February 17, 2025 by: The Motley Fool
Sentiment: Positive
If you're content with market-level returns, investing in an exchange-traded fund (ETF) is the way to go. But if not, you'll need to find stocks that hold the potential to pack more punch.
Read More
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: February 14, 2025 by: Business Wire
Sentiment: Neutral
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 116,725 shares of common stock. Awards were made to nine new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company's Compensation Committ.
Read More
About Summit Therapeutics Inc. (SMMT)
- IPO Date 2015-03-05
- Website https://www.summittxinc.com
- Industry Biotechnology
- CEO Mr. Robert W. Duggan
- Employees 159